Citocinas Hormonas y Factores de Crecimiento

7/31/2019 Citocinas Hormonas y Factores de Crecimiento.

1/19

-(50(0$/=$&

0$7(5,$0(',&$20(23$7,&$',,00812/2*,$&/,1,&$

1829$,36$(',725(

Hormones

Cytokines

neuropeptidesGrowtH faCtors

APPENDIX

HomeopatHic materia medicaof clinical immunology

The vision of

Physiological Regulating Medicine

on the use of physiological low doses of


2/19

All rights reserved.

Reproduction under any form are prohibited without written permission of pubblisher

2010 J mlzc cgh

2010 nv i e l, h

.v. - -l: @v.


3/19

1

Hormones

Cytokines

neuropeptides

GrowtH faCtors

APPENDIX

The vision of



is based on a revolutionary ideain the medical field: restoring the initial physiological conditions of a sick body by usingthe same biological molecules that are usually present in the body and which control and

guide its functions in healthy conditions.

To be precise, these molecules are very well known and extensively studied in MolecularBiology, and it is no mere chance that they are called messenger molecules- substances that

can convey the right instructions for correct function to the various cells of the body.These molecules include

(Ner-vous System messen-gers),(Endocrine System mes-sengers),(Immune System mes-

sengers).There are also

,which are essential tissueregulating and stimulatingmolecules.

It has been acknowledged that these substances play a decisive role in determining eitherhealth or disease, and today it has been ascertained that every disease is the expression of

changes in concentrations either of an increase or of a reduction of these substances.All international medical research is focusing on the study of messenger molecules; thepositive (healing) or negative (disease) fate of several pathological conditions depends onthem and on the possibility of using them for therapeutic purposes

PSYCHE

SOMAPSYCHE

P.N.E.I. NETWORKP.N.E.I. NETWORK

AND MESSENGER MOLECULESAND MESSENGER MOLECULES

INTERLEUKINS

HORMONES

NEUROPEPTIDES

HORMONES


4/19

2

For instance, correcting Immune System alterations through the use of cytokines and en-docrine diseases with hormones is one of the most fascinating and innovative objectives ofresearch centered on applying Molecular Biology to Medicine. But the clinical applicationof this know-how has always come to a standstill when faced with the side effects caused

by the high doses of these substances that have been routinely used until today.

The pharmaceutical technique known as enablesthe administration of OF HORMONES, NEUROPEPTIDES,CYTOKINES AND GROWTH FACTORS to achieve the same therapeutic results ashigh doses but without any side effects.

In November 2009 the prestigious international scientific

reviewpublished the article Low dose oral administration

of cytokines for treatment of allergic asthma. The paperenlarged on the effects of low doses of SKA-activated cytokinesin the treatment of allergic asthma, proving in a clear, evidentand especially reproducible manner that the low dosesadministered during the study produced the same effects ashigh doses in changing a series of clinical and laboratory

parameters typical of the allergic condition.

The opens a new era in options for the clinical use of messenger moleculesand concretises the scientific dream of using biological molecules, such as cytokines,hormones and neuropeptides, in low doses (the only doses that can avoid side effects).

A new frontier has most likely been set for pharmaceutical industries and in the field ofMolecular Biology, and both Italian researchers and the Italian industry are paving the wayin this sector.


5/19

3

Low physiological doses of cytokines activated with the SKA procedure are marketed in ahydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, whichcorresponds to a homeopathic dilution of 4CH1.

The standard posology is 20 drops twice a day.Sublingual administration is recommended.

The duration of therapy differs depending on the clinical condition and on the gravity ofthe disease.Chronic diseases usually require the administration of treatment cycles with minimum du-ration of 2 months. They can be repeated, preferably after a 15-day suspension.In acute diseases therapy is continued until remission of symptoms. At times a massive dosetherapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

Cytokines can be prescribed following two trends.

if the pathological condition is the expression of a ofa certain cytokine, the same cytokine will be used;

if the pathological condition is the expression of an of a certaincytokine, the so-called opposing cytokine will be used.

the cytokine is prescribed to suit the symptoms of the patient.

1 Single cytokines are also available in dilutions of 15CH and 30CH, which are at times

used as maintenance treatment to stabilize therapeutic results achieved with the use of di-lution 4CH.


6/19

4

Anti IL-1 alpha Anti IL-1 alpha 4 CH IL-1 4CH

Anti IL-1 beta Anti IL-1 beta 4 CH IL-1 4CH

GCSF GCSF 4CH IL-10 4CH / IL-4 4CH

IL-1 IL-1 4CH

Anti IL-1 alpha 4CH

Anti IL-1 beta / IL-10 4CHIL-2 IL-2 4CH IL-11 4CH

IL-3 IL-3 4CH IL-10 4CH

IL-4 IL-4 4CH INF-gamma 4CH / IL-12 4CH

IL-5 IL-5 4CH TGF-beta 4CH

IL-6 IL-6 4CH

Acute inflammation:

IL-4 4CH/INF- 4CHChronic inflammation:TNF Alpha 4CH

IL-7 IL-7 4CH IL-10 4CH / TGF-b 1 4CH

IL-8 IL-8 4CH IL-10 4CH / TGF-b 1 4CH

IL-9 IL-9 4CH IL-10 4CH

IL-10 IL-10 4CH IL-1 4CH / TNF 4CH

IL-6 4CHIL-11 IL-11 4CH IL-2 4CH

IL-12 IL-12 4CH IL-4 4CH/IL-10 4CH

INF alpha INF alpha 4CH IL-4 4CH

INF gamma INF gamma 4CH IL-4 4CH

TGF-beta 1 TGF-beta 4CH IL-12 4CH

TNF TNF-alpha 4CH Anti IL-1 4CH+IL-10 4CH


7/19

5

Pain syndromes Acute inflammatory diseases Fever

Pain syndromes Acute inflammatory diseases Fever

Asthenia Sleep disorders Appetite disorders (excessive appetite)

Immunodeficiencies General sickness Subacute pain syndromes Localised inflammations Aging Complementary treatment for tumours Weariness, adynamia Burning sensation in the mouth Sensitivity to viral infections

Haemopoiesis disorders Side effects associated with chemotherapy, radio-

therapy and antiviral treatments Early aging Memory loss Digestive disorders Vertigo with vomiting Skin eruptions Erratic pains

Basic treatment for autoimmune diseases Chronic inflammatory diseases Spastic cramp-like pain Mental fatigue

Intestinal parasitosis Bruise-induced pain Constipation and flatulence Abdominal pains (cramp-like) RRI with IgA deficiency

General sickness Complementary therapy for tumours Appetite disorders (excessive appetite)

Recurrent infections Asthenia Growth and development disorders

Pulsating pain Nervous breakdown and tiredness

Activation of chemotaxis Productive cough Catarrh Acute and chronic stress

Asthenia and drowsiness Erythroid proliferation disorders (synergywith erythropoietin)

Neuralgic pain Chronic catarrh Water retention

Chronic inflammatory diseases Itching with a burning sensation Reddened mucous tissue Chronic pain syndromes Vomiting/loss of appetite

Pyrosis and gastric acid hypersecretion Memory disorders Haemopoiesis disorders Psoriasis Abdominal bloating Basic regulation of patients undergoing immunotherapy Growth and development disorders Pulsating pain Nervous breakdown and tiredness

Allergies Food intolerances Complementary therapy for tumours Recurrent nighttime cough Nasal obstruction and nose itch Paroxysmal sneezing Allergy-induced hyperlacrimation Swollen and reddened skin

Recurrent viral infections Articular pain Asthenia Sudden pain with numbing Painful muscle spasms

Chronic viral infections Allergic syndromes Complementary therapy for tumours Asthenia Spastic muscle pain

Complementary therapy for tumours

Chronic bacterial infections Confusion at night with sleep disorders Myalgia and stiffness especially in the morning


8/19

6

2 For single hormones or single neuropeptides marketed in dilutions of 4CH, dilutions of15CH/30CH are also available. They are at times used as maintenance therapy to stabilisetherapeutic results achieved with the use of the 4CH dilution.

3 Single hormones are also available in a 30DH dilution, which is at times used as maintenancetreatment to stabilise therapeutic results achieved with the use of dilution 6DH.

Low physiological doses of hormones activated with the SKA procedure are marketed in ahydroalcoholic solution in 30 ml bottles. The drug concentration is in picograms/ml, whichcorresponds to the homeopathic dilution of 4CH for some (Beta-Endorphin, Melatonin,Somatostatin)2, and in nanograms/ml, corresponding to the homeopathic dilution of 6DHfor others3.


The duration of treatment differs depending on the clinical condition and on the gravity ofthe disease.Chronic diseases usually require the administration of treatment cycles with minimum du-ration of 2 months. They can be repeated, preferably after a 15-day suspension.In acute diseases therapy is continued until remission of symptoms. At times a massive dosetherapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

Hormones and neuropeptides can be prescribed following two trends.

if the pathological condition is the expression of a ofa certain hormone or neuropetide, the same hormone will be used;

If the pathological condition is the expression of an of a certain

hormone, the so-called opposing hormone will be used consistently with the physiologyof negative feedback.

the hormone is prescribed to suit the symptoms of the patient.


9/19

7

ACTH ACTH 6DH TSH 6DH

Beta-ENDORPHIN Beta-ENDORPHIN 4CH no opposing hormone

Beta-ESTRADIOL beta-ESTRADIOL 6DH PROGESTERON 6DH

CALCITONIN CALCITONIN 6DH PARATHYROIDHORMONE 6DH

DOPAMIN DOPAMIN 6DH

SEROTONIN 6DH

MELATONIN 4CH

PROLACTIN 6DH

FSH FSH 6DH beta-ESTRADIOL 6DH

GH IGF-1 6DH SOMATOSTATIN 4CH

LH LH 6DH PROGESTERON 6DH

MELATONIN MELATONIN 4CH PROLACTIN 6DH

OXYTOCIN OXYTOCIN 6DHPROGESTERONE 6DH

Beta-ESTRADIOL 6DH

PARATHYROID

HORMONE

PARATHYROID

HORMONE 6DHCALCITONIN 6DH

PROGESTERONE PROGESTERONE 6DH Beta-ESTRADIOL 6DH

PROLACTIN PROLACTIN 6DH MELATONIN 4CH

SOMATOSTATIN SOMATOSTATIN 4CHIGF-1 6DH

PROLACTIN 6DH

T3 T3 6DH SOMATOSTATIN 4CH

T4 T4 6DH SOMATOSTATIN 4CH

TSH TSH 6DH ACTH 6DHSOMATOSTATIN 4CH


10/19

8

Asthenia Aging Chronic stress Loss of appetite Hypervagotonia

Pain of diverse origins

Female hormone cycle disorders and infertility Aging Hot flushes Sagging skin Stress

Osteoporosis Bone pain

Chronic Fatigue Syndrome Mental Strain Mood disorders Lack of attentiveness Lack of sexual desire Decreased sexual arousal Supportive therapy of Parkinson's disease

Female hormone cycle disorders and infertility Aging Ovarian polycystosis Low female libido

Aging Female hormone cycle disorders and infertility Low male libido

Sleep disorders Circadian rhythm and organ function alterations Stress Mood disorders with unstable mood Complementary therapy for tumours Hypersympathicotonia

Jet lag

Mood disorders Social phobya Decreased sexual satisfaction Supportive treatment during delivery Supportive treatment of Autism

Cramp-like pains Asthenia

Premenstrual syndrome Female hormone cycle disorders and infertility Menstrual pain Intermenstrual spotting Ovarian polycystosis

Mood disorders with unstable mood Muscle weakness

Mood disorders with unstable mood Headache Diet disorders

Oncological diseases Hyperthyroidism

Hypothyroidism Tendency toward overweight

Growth disorders Physical asthenia Neurasthenia

Sleep disorders Mood disorders and unstable mood

Neurasthenia Water retention


11/19

Low physiological doses of growth factors activated with the SKA procedure are marketedin a hydroalcoholic solution of 30 ml bottles. The drug concentration is in picograms/ml,which corresponds to a homeopathic dilution of 4CH4.


The duration of therapy differs depending on the clinical condition and on the gravity ofthe disease.Chronic diseases usually require the administration of treatment cycles with minimum du-ration of 2 months. They can be repeated, preferably after a 15-day suspension.In acute diseases therapy is continued until remission of symptoms. At times a massivedose therapy can be applied with 10 drops every 20 minutes for maximum 2 hours.

Growth factors can be prescribed following two trends.

if the pathological condition is the expression of a ofa certain growth factor, the same growth factor will be used.

the growth factor is prescribed to suit the symptoms of the patient.

4 Single growth factors are also available in dilutions 15C and 30C, which are at times used

as maintenance therapy to stabilise therapeutic results achieved with the use of dilution4CH.

9


12/19

10

Neurological damage (duringdevelopment or subsequent to injuries)

Outcome of psychic shock Mental tiredness Stress Autism Cerebral aging Tingling and numbing of hands

and feet

Muscle stiffness

Neurological damage (duringdevelopment or subsequent to injuries) Sight disorders Cerebral aging Appetite control Cerebral aging

Skin rashes Skin aging Itching Chapped skin Gastric acid hypersecretion Feeling of heaviness in the epigastrium

with soreness Blurred vision with scintillating scotomas Hypersensitivity to pain

Aging Cicatrisation difficulty Articular symptoms with limited movement

Skin aging

Mental tiredness Muscle weakness Damaged myelin sheath

Sensitivity to infectious diseases Immune response triggered in chronic

and autoimmune diseases.

Growth disorders Aging Memory disorders (stimulates

hippocampus function)

Neuralgic pain Memory disorders Mood disorders

Skin thinning and ulcers Loss of strength in limbs, easy tiredness Sadness and loss of interest

Muscle weakness Mood disorders CNS and PNS diseasesNeurological damage (during

development and subsequent to injuries)

Muscle weakness Mood disorders CNS and PNS disorders Neurological damage (during

development and subsequent to injuries) Pain syndromes

Aging Wrinkles Mytogenic activity

Chronic pain syndromes Autoimmune diseases Chronic inflammations


13/19

11

INTERLEUKIN-5 4CH

INTERLEUKIN-11 4CH

INTERLEUKIN-8 4CH

Anti INTERLEUKIN-1alpha 4CH/Anti INTERLEUKIN-1beta 4CH

INTERLEUKIN-2 4CH / FGF 4CH / IGF-1 4CH / PDGF 4CH /ACTH 6DH / Beta-ESTRADIOL 6DH / FSH 6DH / LH 6DH

INF-gamma 4CH+INTERLEUKIN-12 4CH

INTERLEUKIN-12 4CH + INTERFERON-gamma 4CH /INTERLEUKIN-13 4CH

INTERLEUKIN-12 4CH

CNTF 4CHINTERLEUKIN-1 beta 4CH /

INTERLEUKIN-6 4CH

INF-alpha 4CH

FGF 4CH

INTERLEUKIN-1 beta 4CH / INTERLEUKIN-7 4CH /INF-alpha 4CH / INF-gamma 4CH / ACTH 6DH /

PARATHYROID HORMONE 6DHINTERLEUKIN-9 4CH

BDNF 4CH

TGF-beta 1 4CH

INTERLEUKIN-11 4CH

INTERLEUKIN-4 4CH

EGF 4CH

CALCITONIN 6DHINTERLEUKIN-5 4CH


14/19

12

INTERLEUKIN-2 4CH

INTERLEUKIN-8 4CH

BDNF 4CH / CNTF 4CH

EGF 4CH

INTERLEUKIN-8 4CH

TNF-alpha 4CH

INTERLEUKIN-9 4CH

DOPAMIN 6DH

TGF-beta 1 4CH

INTERLEUKIN-4 4CH /

INTERLEUKIN-10 4CHInterleuchina-10 4CH / Beta-ENDORFINA 4CH /TGF-beta 1 4CH

INF-gamma 4CH

ACTH 6DH

FGF 4CH

MELATONIN 4CH

NT3 4CH/NT4 4CH

SOMATOSTATIN 4CH /INTERLEUKIN-12 4CH / INTERFERON-gamma 4CH /INTERLEUKIN-2 4CH / MELATONIN 4CH / TNF-alpha 4CH

TNF-alpha 4CH

INTERLEUKIN-5 4CH

PARATHYROID HORMONE 6DH

INTERLEUKIN-10 4CH + Anti IL-1

G1 4CH

DOPAMIN 6DH

OXYTOCIN 6DH

SEROTONIN 6DH

INTERLEUKIN-3 4CH

DOPAMIN 6DH

INTERLEUKIN-3 4CHINTERLEUKIN-3 4CH


15/19

13

INTERLEUKIN-9 4CH

EGF 4CH

Beta-ESTRADIOL 6DH /

FSH 6DH / LH 6DH / PROGESTERON 6DHAnti IL-1 4CH

INTERLEUKIN-12 4CH

EGF 4CH

INTERLEUKIN-2 4CH / INTERLEUKIN-6 4CH

INTERLEUKIN-7 4CH /INTERLEUKIN-11 4CH

IGF-1 4CH / T4 6DHSEROTONIN 6DH


EGF 4CH

ACTH 6DH

MELATONIN 4CH

SOMATOSTATIN 4CH

T3 6DHBeta-ESTRADIOL 6DH

GCSF 4CH

INTERLEUKIN-2 4CH

PROGESTERON 6DH

INTERLEUKIN-5 4CH

EGF 4CH

INTERLEUKIN-10 4CH

MELATONIN 4CH

DOPAMIN 6DH

DOPAMIN 6DH

INTERLEUKIN-2 4CH

ACTH 6DH

NGF 4CHFSH 6DH / OXYTOCIN6DH / DOPAMIN 6DH


16/19

14

LH 6DH / DOPAMIN 6DH

NGF 4CH / IGF-1 4CH (stimulates hippocampusfunction) / INTERLEUKIN-11 4CH

INTERLEUKIN-3 4CH

PROGESTERON 6DH

INTERLEUKIN-4 4CH

DOPAMIN 6DH

BDNF 4CH / G1 4CH

NGF 4CH / NT3 4CH / NT4 4CH /OXYTOCIN 6DH / DOPAMIN 6DH

MELATONIN 4CH /SEROTONIN 6DH / TRYPTOPHAN 6DH

G1 4CH / NT3 4CH / NT4 4CH / PROLACTIN 6DH

TNF-alpha 4CH

PDGF 4CH

INTERLEUKIN-12 4CH

INTERLEUKIN-7 4CH /INTERLEUKIN-11 4CH

NGF 4CH / INTERLEUKIN-9 4CHT4 6DH / TSH 6DH

BDNF 4CH / CNTF 4CH / NT3 4CH / NT4 4CH

CALCITONIN 6DH

BDNF 4CH

FSH 6DH / PROGESTERON 6DH

Beta-ENDORPHIN 4CHBeta-ENDORPHIN 4CH / Anti INTERLEUKIN-1 4CH /

NT4 4CH

INF-alpha 4CH

INTERLEUKIN-12 4CH

T4 6DH


PROGESTERON 6DH / Beta-ENDORPHIN 4CHINTERLEUKIN-8 4CH


17/19

15

INTERLEUKIN-11 4CH / INTERLEUKIN-4 4CH /INTERLEUKIN-10 4CH

INTERLEUKIN-11 4CH

INTERLEUKIN-7 4CH

INTERLEUKIN-12 4CH

INF-alpha 4CH

INTERLEUKIN-10 4CH

INTERLEUKIN-5 4CH

NGF 4CH

Beta-ESTRADIOL 6DH

GCSF 4CH

INTERLEUKIN-2 4CH

INTERLEUKIN-3 4CH

CNTF 4CH

EGF 4CH / FGF 4CH

INTERLEUKIN-3 4CH

EGF 4CH

NGF 4CH

MELATONIN 4CH / TRIPTOPHAN 6DH /INTERLEUKIN-1 beta 4CH

OXYTOCIN 6DH

INTERLEUKIN-4 4CH

INF-gamma 4CH

BDNF 4CH

BDNF 4CH / Beta-ESTRADIOL 6DH / MELATONIN 4CH

INTERLEUKIN-2 4CH / Beta-ENDORPHIN 4CH

INF-alpha 4CH

OXYTOCIN 6DH

OXYTOCIN 6DH

DOPAMIN 6DH

INTERLEUKIN-12 4CHT3 6DH


18/19

BDNF 4CH

INTERLEUKIN-3 4CH

INTERLEUKIN-10 4CH

INTERLEUKIN-9 4CH / TSH 6DH

INTERLEUKIN-2 4CH

PDGF 4CH

16


19/19

-(50(0$/=$&

0$7(5,$0(',&$20(23$7,&$',,00812/2*,$&/,1,&$

1829$,36$(',725(

Hormones

Cytokines

neuropeptides

GrowtH faCtors

APPENDIX

HomeopatHic materia medica

of clinical immunology

The vision of



Documents

Citocinas Hormonas y Factores de Crecimiento